This article was originally published in RAJ Devices
Concern over effects of new US patent rule
You may also be interested in...
The Phase III clinical trial showed a noticeable placebo effect compared with OV101.
The company will invest $1.2bn over the next four years to expand and upgrade its manufacturing capacity for pre-fillable syringes and advanced drug delivery systems across seven manufacturing facilities.
Beneficiaries in nursing homes and in rural areas will benefit from a telehealth expansion in the final CMS physician fee schedule rule.